Dr. Frydman is a seasoned healthcare executive with diverse industry experience. Prior to Joining Aurum, he served as the Chief Business Officer of FutuRx, the drug development incubator established by J&J, Orbimed and Takeda under franchise from the Israeli Innovation Authority. In this position, he played a key role in establishing multiple new drug development startup companies based on sourcing and licensing of breakthrough drug technologies in Israel and abroad. Prior to that, Dr. Frydman served for 10 years as the COO of Aposense Ltd., a drug development and molecular imaging company (TASE: APOS), with responsibilities across business development, operations and finance. Before joining Aposense, he served as a Senior Business Development manager in GE Healthcare Europe (based in France), doing Healthcare M&A across Europe. Dr. Frydman holds an MBA from the Ecole des Ponts, Paris, France, and a PhD in Chemistry (nanotechnology) from the Weizmann Institute of Science.